Related Experiment Video
Updated: Aug 30, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Antenatal steroid treatment prevents severe hyperkalemia in very low-birthweight infants
Naoki Uga1, Yuko Nemoto, Tetsuya Ishii
1Division of Neonatology, Perinatal Center, Toho University School of Medicine, Otaku, Tokyo, Japan. naokiuga@med.toho-u.ac.jp
Insights
Antenatal steroid treatment significantly lowers serum potassium in very low-birthweight (VLBW) infants, reducing cardiac arrhythmia and the need for glucose-insulin therapy. This finding aids in managing hyperkalemia in premature infants.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Biochemistry
Background:
- Hyperkalemia is a common and potentially dangerous condition in very low-birthweight (VLBW) infants, sometimes leading to cardiac arrhythmias.
- Identifying factors that contribute to elevated serum potassium levels in this vulnerable population is crucial for effective management.
Purpose of the Study:
- To investigate the impact of antenatal steroid treatment on serum potassium concentrations in VLBW infants.
- To identify risk factors associated with severe hyperkalemia in VLBW infants.
Main Methods:
- A retrospective comparative analysis of 140 VLBW infants requiring mechanical ventilation.
- Comparison of serum potassium levels at 24 and 48 hours of age between infants whose mothers received antenatal steroids and those who did not.
- Risk factor analysis for severe hyperkalemia using multiple linear regression and Pearson's partial correlation.
Main Results:
- Antenatal steroid treatment significantly reduced serum potassium concentrations at 24 and 48 hours.
- The incidence of cardiac arrhythmia and the need for glucose-insulin treatment for hyperkalemia were lower in infants exposed to antenatal steroids.
- Serum potassium levels were associated with antenatal steroid treatment, fluid intake, serum sodium, gestational age, and blood urea nitrogen, but not urine output or serum creatinine.
Conclusions:
- Antenatal steroid hormone treatment is effective in reducing early hyperkalemia in VLBW infants.
- This treatment also decreases the incidence of cardiac arrhythmia and the requirement for glucose-insulin therapy in this population.
Background:
Hyperkalemia is seen quite often in very low-birthweight (VLBW) infants and concentrations sometimes become high enough to cause cardiac arrhythmia. The purpose of the present study was to identify factors that increase serum concentrations of potassium in VLBW infants.
Methods:
Retrospective comparative analysis was performed on 140 VLBW infants who had been admitted to the Toho University Perinatal Center between January 1993 and December 1999 and needed mechanical ventilation for respiratory distress. Serum concentrations of potassium at 24 and 48 h of age were compared in two groups of infants, those whose mothers did and did not receive antenatal steroid treatment. Risk factors for severe hyperkalemia were analyzed by multiple linear regression models and Pearson's partial correlation analysis.
Results:
Antenatal steroid treatment reduced serum potassium concentrations significantly at 24 and 48 h, as well as the incidence of cardiac arrhythmia and necessity for glucose insulin treatment for severe hyperkalemia. Multiple linear regression showed the serum potassium concentration at 24 h of age was associated with antenatal steroid hormone treatment, 24 h fluid intake volume, serum sodium concentrations at 24 h, gestational weeks and sampling site. Serum concentration of potassium at 48 h of age was associated with blood urea nitrogen, gestational week, serum sodium concentration at 48 h of age and fluid intake between 24 and 48 h of age. Urine output volume and serum creatinine concentrations were not correlated with potassium concentrations at either age.
Conclusion:
Antenatal steroid hormone treatment can reduce early hyperkalemia in VLBW infants and also the incidence of cardiac arrhythmia and the use of glucose insulin treatment.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acute Kidney Injury V: Interprofessional Care
Teratogenicity
Acute Kidney Injury IV: Diagnostic Studies and Prevention